Folgen
Bjoern Papke
Bjoern Papke
Bestätigte E-Mail-Adresse bei charite.de - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
G Zimmermann, B Papke, S Ismail, N Vartak, A Chandra, M Hoffmann, ...
Nature 497 (7451), 638-642, 2013
6102013
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
KL Bryant, CA Stalnecker, D Zeitouni, JE Klomp, S Peng, AP Tikunov, ...
Nature medicine 25 (4), 628-640, 2019
3602019
Drugging RAS: Know the enemy
B Papke, CJ Der
Science 355 (6330), 1158-1163, 2017
2862017
KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport
M Schmick, N Vartak, B Papke, M Kovacevic, DC Truxius, L Rossmannek, ...
Cell 157 (2), 459-471, 2014
2202014
Identification of pyrazolopyridazinones as PDEδ inhibitors
B Papke, S Murarka, HA Vogel, P Martín-Gago, M Kovacevic, DC Truxius, ...
Nature communications 7 (1), 1-9, 2016
1302016
Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic CancerKRASG12R Is Impaired in PI3K Signaling and Macropinocytosis
GA Hobbs, NM Baker, AM Miermont, RD Thurman, M Pierobon, TH Tran, ...
Cancer discovery 10 (1), 104-123, 2020
882020
The autodepalmitoylating activity of APT maintains the spatial organization of palmitoylated membrane proteins
N Vartak, B Papke, HE Grecco, L Rossmannek, H Waldmann, C Hedberg, ...
Biophysical journal 106 (1), 93-105, 2014
752014
Precise measurement of protein interacting fractions with fluorescence lifetime imaging microscopy
KA Walther, B Papke, MB Sinn, K Michel, A Kinkhabwala
Molecular Biosystems 7 (2), 322-336, 2011
492011
Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS mutant cancers
I Ozkan-Dagliyan, JN Diehl, SD George, A Schaefer, B Papke, ...
Cell reports 31 (11), 107764, 2020
462020
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer
JN Diehl, JE Klomp, KR Snare, PS Hibshman, DR Blake, ZD Kaiser, ...
Journal of Biological Chemistry 297 (5), 2021
82021
Targeting p130Cas-and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition
AM Waters, TO Khatib, B Papke, CM Goodwin, GA Hobbs, JN Diehl, ...
Cell reports 35 (13), 109291, 2021
62021
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment
JE Klomp, YS Lee, CM Goodwin, B Papke, JA Klomp, AM Waters, ...
Cell reports 37 (9), 110060, 2021
52021
Silencing of oncogenic KRAS by mutant-selective small interfering RNA
B Papke, SH Azam, AY Feng, C Gutierrez-Ford, H Huggins, PS Pallan, ...
ACS Pharmacology & Translational Science 4 (2), 703-712, 2021
42021
Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer (Nature Medicine,(2019), 25, 4,(628-640), 10.1038/s41591-019-0368-8)
KL Bryant, CA Stalnecker, D Zeitouni, JE Klomp, S Peng, AP Tikunov, ...
Nature medicine 26 (6), 982, 2020
42020
Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy InhibitorsIGF1R Inhibition Enhances Dual ERK and Autophagy Inhibition
CA Stalnecker, KR Grover, AC Edwards, MF Coleman, R Yang, ...
Cancer Research 82 (4), 586-598, 2022
32022
Abstract B32: Silencing of oncogenic KRAS by a mutant-favoring short interfering RNA
B Papke, AED Van Swearingen, AY Feng, SH Azam, EB Harrison, R Yang, ...
Molecular Cancer Research 18 (5_Supplement), B32-B32, 2020
12020
Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer
CM Goodwin, S Javaid, AM Waters, B Papke, R Yang, M Pierobon, ...
Cancer Research 79 (13_Supplement), LB-287-LB-287, 2019
12019
The Spatial Organization of Ras Signaling
B Papke, M Schmick, N Vartak, PIH Bastiaens
Ras Superfamily Small G Proteins: Biology and Mechanisms 1, 173-188, 2014
12014
Defining the KRAS-regulated kinome in KRAS-mutant pancreatic cancer
JN Diehl, JE Klomp, KR Snare, DR Blake, PS Hibshman, ZD Kaiser, ...
bioRxiv, 2021
2021
MA27. 06 Therapeutic Silencing of Oncogenic KRAS With a Mutant-Specific Short Interfering RNA
C Pecot, A Van Swearingen, B Papke
Journal of Thoracic Oncology 13 (10), S456, 2018
2018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20